|
The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer. |
|
|
Leadership - Astellas Pharma; Johnson & Johnson |
Honoraria - Astellas Pharma; Johnson & Johnson |
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Johnson & Johnson; Sanofi |
Speakers' Bureau - Astellas Pharma; GlaxoSmithKline; Johnson & Johnson; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; GlaxoSmithKline (I); Johnson & Johnson |
|
|
Employment - Astellas Pharma |
|
|
Consulting or Advisory Role - Astellas Pharma |
|
|
Employment - Astellas Pharma |
Research Funding - Novartis (I) |
|
|
Employment - Abbott Laboratories; Astellas Pharma |
Stock and Other Ownership Interests - Abbott Laboratories |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - AstraZeneca (I) |
|
|
No Relationships to Disclose |